Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
26.91
+0.77 (2.95%)
At close: Nov 15, 2024, 4:00 PM
27.19
+0.28 (1.04%)
After-hours: Nov 15, 2024, 7:35 PM EST
Cassava Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
1.29B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.26B |
Indivior | 1.18B |
Guardian Pharmacy Services | 1.17B |
Tilray Brands | 812.04M |
STAAR Surgical Company | 341.22M |
Schrödinger | 193.35M |
Day One Biopharmaceuticals | 101.95M |
Praxis Precision Medicines | 1.61M |
SAVA News
- 4 days ago - Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease - Seeking Alpha
- 8 days ago - Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Cassava Sciences Reports Q3 2024 Financial and Operating Results - GlobeNewsWire
- 15 days ago - Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewsWire
- 5 weeks ago - What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? - Benzinga
- 7 weeks ago - Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims - Investopedia
- 7 weeks ago - SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty - Benzinga
- 7 weeks ago - Cassava Sciences settles SEC charges of ‘misleading' Alzheimer's trial claims - Market Watch